Simultaneous ALS and SCA2 associated with an intermediate-length ATXN2 CAG-repeat expansion

Amyotroph Lateral Scler Frontotemporal Degener. 2021 Nov;22(7-8):579-582. doi: 10.1080/21678421.2020.1853172. Epub 2020 Dec 7.

Abstract

Spinocerebellar ataxia type 2 (SCA2) and amyotrophic lateral sclerosis (ALS) share a common molecular basis: both are associated with CAG-repeat expansion of ATXN2 and TDP-43-positive neuronal cytoplasmic inclusions. To date, the two disorders are viewed as clinically distinct with ALS resulting from 30-33 CAG-repeats and SCA2 from >34 CAG-repeats. We describe a 67-year old with a 32 CAG-repeat expansion of ATXN2 who presented with simultaneous symptoms of ALS and SCA2. Our case demonstrates that the clinical dichotomy between SCA2 and ATXN2-ALS is false. We suggest instead that CAG-repeat expansion length determines the timing of SCA2 clinical symptoms relative to onset of ALS; consistent with this age of onset of SCA2 but not ATXN2-ALS, is dependent upon expansion length. Review of the literature and our local cohort provides evidence for occurrence of ALS in late stage SCA2, which may be under-recognised by clinicians who think of the two diseases as distinct.

Keywords: Risk; genetics; neurophysiology.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Amyotrophic Lateral Sclerosis* / genetics
  • Ataxin-2 / genetics
  • Cohort Studies
  • Humans
  • Spinocerebellar Ataxias* / genetics
  • Trinucleotide Repeat Expansion / genetics

Substances

  • ATXN2 protein, human
  • Ataxin-2